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DOI 10.1016/j.ccr.2009.11.025SUMMARYThe p53 gene is mutated in many human tumors. Cells of such tumors often contain abundant mutant p53
(mutp53) protein, which may contribute actively to tumor progression via a gain-of-function mechanism.
We applied ChIP-on-chip analysis and identified the vitamin D receptor (VDR) response element as overrep-
resented in promoter sequences bound by mutp53. We report that mutp53 can interact functionally and
physically with VDR. Mutp53 is recruited to VDR-regulated genes and modulates their expression, augment-
ing the transactivation of some genes and relieving the repression of others. Furthermore, mutp53 increases
the nuclear accumulation of VDR. Importantly, mutp53 converts vitamin D into an antiapoptotic agent. Thus,
p53 status can determine the biological impact of vitamin D on tumor cells.INTRODUCTION
The p53 tumor suppressor is a major barrier against cancer
progression. The p53 pathway is impaired in almost all human
cancers (Vogelstein et al., 2000). About 50% of human cancers
carry p53 mutations (Soussi and Wiman, 2007), mostly missense
mutations resulting in overproduction of mutant p53 (mutp53)
protein (Weisz et al., 2007b). This might imply a strong selection
for mutp53 expression in carcinogenesis. Indeed, p53 mutations
result not only in lossof tumor-suppressingactivitiesby themutant
allele but also in trans-dominant inactivation of the remaining
wild-type p53 (wtp53) (Shaulian et al., 1992). Importantly, at least
some cancer-associated mutp53 variants acquire oncogenic
activities, defined as gain of function (GOF) (Weisz et al., 2007a).
Specifically, mutp53 can enhance proliferation, survival, and
tumorigenicity in mice (Bossi et al., 2006; Weisz et al., 2004).
Furthermore, at least for some types of cancer, patients harboring
particular missense p53 mutations in their tumors tend to be less
responsive to chemotherapy (Soussi and Beroud, 2001).Significance
Mutation of the p53 tumor suppressor gene is themost commo
only loses its tumor suppressor activity but gains oncogenic fun
for cancer therapy. Likewise, vitamin D and its analogs are be
provide a mechanism for mutp53 GOF, based on the interac
have clinical implications and suggest that p53 status should
cancer therapy.Mechanistically, mutp53 can exert a dominant-negative
effect over the p53 family members p63 and p73 and inhibit
their biochemical and biological activities (Irwin et al., 2003;
Lang et al., 2004). Moreover, mutp53 can regulate specific
sets of target genes independently of p63 and p73 (Lin et al.,
1995; Zalcenstein et al., 2003; Weisz et al., 2004; Scian et al.,
2004). Accordingly, the transcriptional activation domain of
p53 is necessary for gene regulation by mutp53 as well as for
its interference with apoptosis (Matas et al., 2001). Most
cancer-associated p53 mutations occur in the DNA binding
domain (DBD) and abolish the ability of the protein to bind to
the specific DNA sequences recognized by wtp53. Hence, the
ability of mutp53 to regulate gene expression may require
interactions with other proteins that tether it to the DNA, as
suggested for NF-Y (Di Agostino et al., 2006) and NF-kB
(Weisz et al., 2007a).
In this study, we used chromatin immunoprecipitation (ChIP)
coupled with microarray analysis (ChIP-on-chip) to identify
DNA regions selectively associated with mutp53.n genetic alteration in human cancer. Oncemutated, p53 not
ctions. Indeed, p53 is being examined as an important target
ing evaluated as potential anti-cancer agents. Our findings
tion between p53 and VDR. The results we obtained may
be considered when contemplating vitamin D analogs for
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Table 1. Gene Promoters Preferentially Bound by Mutp53
Spot Name p Value Binding Ratio Refseq Location Start End
VIPR2 1.3E14 11.26 NM_003382 chr7 158354273 158355212
KIAA1243 8.2E12 6.42 NM_014048 chr16 14325637 14326400
MAGEH1 1.4E09 10.23 NM_014061 chrX 54444648 54445501
PRDM5_2,0 3.5E09 10.23 chr4 122304464 122305398
MLLT2_1,0 1.3E08 4.24 chr4 88384955 88385854
PGBD1_0,0 7.0E08 6.23 chr6 28356784 28357645
ECE2 1.0E07 3.87 NM_014693 chr3 185314038 185314863
TGIF2_0,1 3.2E06 5.50 chr20 35887837 35888790
FLJ22031 4.4E06 4.20 NM_025074 chr4 79803252 79803961
HIRA_0,0 1.7E06 2.37 chr22 17793360 17794375
GHR 2.0E05 4.90 NM_000163 chr5 42468831 42469760
EMK1 2.1E05 2.46 NM_004954 chr11 63430695 63431630
ZFP161_0,0 2.3E05 3.01 chr18 5283120 5284074
CPT1B 3.1E05 2.69 NM_004377 chr22 49149214 49150151
SKP2 6.0E05 2.36 NM_032637 chr5 36196967 36197905
NFS1 6.5E05 2.12 NM_021100 chr20 35002468 35003216
IGFBP2_0,0 6.8E05 2.07 chr2 217699947 217700698
ECRG4 7.2E05 2.22 NM_032411 chr2 106302804 106303731
TIEG 7.2E05 2.36 NM_005655 chr8 103624358 103625159
HARP11 9.2E05 2.47 NM_018477 chr14 56656150 56656961
LIG1 9.2E05 2.45 NM_000234 chr19 53365208 53366136
HOXB2_0,2 1.0E04 2.07 chr17 47094840 47095801
STATH 1.2E04 2.11 NM_003154 chr4 71177406 71178146
TUBA6 1.2E04 1.98 NM_032704 chr12 47944440 47945247
FLJ21415 1.4E04 2.20 NM_024738 chr12 115587568 115588515
MSX1_0,0 1.4E04 2.4 chr4 4925239 4926223
miR-219_i 3.6E04 2.07 chr5 33222063 33222888
PCDHA7 4.2E04 2.7 NM_018910 chr6 122304464 122305398
TGFB1_0,1 5.4E04 2.1 chr19 46550014 46551047
TMEM2 6.0E04 2.43 chr9 69840372 69840999
Results of ChIP-on-chip performed on mutp53 in SKBR3 cells. Thirty of the promoter and regulatory sequences exhibiting the highest statistical
significance for mutp53 binding.
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Identification of Promoters Bound by Mutp53
To elucidate the molecular basis for the ability of mutp53 to
modulate specific gene expression, ChIP coupled with promoter
microarray hybridization (ChIP-on-chip; see Experimental Pro-
cedures) analysis was performed on SKBR3 breast cancer-
derived cells, which harbor an endogenous mutant, p53R175H.
About 70 promoters were boundwith a p value of <0.001. Table 1
lists 30 genes whose promoters scored highest.
Identification of Transcription Factor Motifs
Overrepresented in Promoters Bound or Regulated
by Mutp53
A bioinformatics analysis was next performed on the ChIP-on-
chip data in order to identify transcription factor binding motifs
overrepresented in mutp53-bound promoters. Every gene was
scanned for binding sites from 1000 bp upstream to 200 bp
downstream from its transcription starting site, for overrepresen-274 Cancer Cell 17, 273–285, March 16, 2010 ª2010 Elsevier Inc.tation of 414 different binding motifs relative to the genes across
the whole genome (Tabach et al., 2007). A similar analysis was
performed on the putative promoters ofmutp53-regulated genes
identified in an expression microarray experiment, performed
with p53 null H1299 lung adenocarcinoma cells stably trans-
fectedwith p53R175H (Weisz et al., 2004). Table 2 lists transcrip-
tion factors exhibiting a statistically significant association with
mutp53 in at least one of the two experiments. Remarkably,
the vitamin D receptor/retinoid X receptor (VDR/RXR) response
element (VDRE; consensus: AGGTCAnnnAGGTCA), which
mediates the transcriptional effects of vitamin D, scored positive
in both theChIP-on-chip and the expressionmicroarray analysis.
When a similar bioinformatics analysis was applied to ChIP-on-
chip data obtained from wtp53-expressing U2OS cells using
the same arrays, it identified p53RE as the most significant motif
but did not score VDRE (Table S1, available online), thus confirm-
ing the validity of the analysis. Two motifs, HEN-1 and MEF-2,
were found to be overrepresented in promoters bound by both
wtp53 and mutp53.
Table 2. Transcription Factor Motifs Overrepresented in
Promoter Sequences Preferentially Bound by Mutp53
TF Name
SKBR3
ChIP-on-Chip
H1299
Expression Array
V$VDR_RXR.01 1.08E04 8.10E04
V$ELF2.01 1 3.85E04
V$PAX8.01 3.92E04 1
V$HEN1.01 2.01E01 3.98E04
V$PDX1.01 7.64E04 3.36E01
V$E4BP4.01 1 7.50E03
V$PAX6.02 5.92E01 1.25E03
V$MYT1.02 1 1.34E03
V$HIVEP1_01 1 1.54E03
V$NFY.02 1.58E03 5.02E01
V$NFKAPPAB.02 9.60E03 1.70E03
V$MYCMAX.03 1.93E01 1.73E03
V$BKLF.01 1.80E03 1
V$MUSCLE_INI. 1.93E03 2.08E01
V$OCT1P.01 2.15E03 1
V$MAZ.01 2.28E03 1E02
Bold highlighting indicates a statistically significant p value for a
TF motif overrepresentation in promoter sequences identified either by
ChIP-on-chip (SKBR3) or expression array (H1299).
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in Promoters of Vitamin D Target Genes
To confirm the interaction of mutp53 with VDR/RXR-containing
promoters and to assess the impact of the active form of vitamin
D3 [1a25(OH)2D3] on such interaction, a pool of SKBR3 cells
stably transfected with control short hairpin RNA (shRNA) and
another pool transfected with p53 siRNA (Figure S1A) were
subjected to ChIP analysis. Cells were either grown in medium
containing charcoal-stripped serum to deplete residual vitamin
D3 or treated with vitamin D3. Immunoprecipitation was per-
formed using antibodies specific for either p53 or VDR, or beads
only as a non-specific control. The immunoprecipitated DNA
was subjected to qPCR analysis with primers specific for the
regions encompassing putative VDREs in the promoters of the
HIRA and TGF-b1 genes, which scored positive for mutp53
binding in the ChIP-on-chip screen. Significant binding of
mutp53 to the VDRE-containing regions of both promoters was
clearly detectable (Figure 1A), but was not seen with a ChIP-
control genomic sequence (bottom panel). Vitamin D3 treatment
markedly increased VDR binding. Remarkably, knockdown of
endogenous mutp53 reduced the binding not only of mutp53
but also of VDR. Importantly, vitamin D3 elicited a further
increase in mutp53 binding relative to non-treated cells. Thus,
mutp53 indeed associates with VDRE-containing regions within
specific genes, and this is further enhanced by vitamin D3.
To further validate the binding of mutp53 to VDRE, we per-
formed an in vitro ‘‘Southwestern’’ assay, in which nuclear
extracts are incubated with membrane-immobilized synthetic
oligonucleotides followed by western blot analysis to detect
proteins that bound to the oligonucleotides. As seen in Fig-
ure S1B, vitamin D3 treatment augmented the binding of VDR
to a wild-type but not mutant VDRE sequence, as expected(IB: VDR). Importantly, mutp53 displayed weak specific binding
to the VDRE under basal conditions, which was significantly
augmented upon vitamin D3 treatment (IB: p53). Of note,
mutp53 did not bind to a wtp53 binding sequence (wtp53RE).
Mutp53 Enhances Vitamin D3-Induced Transcription
To investigate the functional consequences of the recruitment of
mutp53 to VDRE-containing promoters, the firefly luciferase
gene was placed downstream to three tandem copies of a
canonical VDRE or a mutant incapable of VDR/RXR binding
(mVDRE), In p53 null H1299 cells, cotransfection of expression
plasmids encoding either p53R175H or p53R273H led to a
mild increase in the transcriptional activity of the wild-type but
not mutant VDRE promoter. Vitamin D3 increased transcription
from the wild-type but not mutant VDRE (Figure 1B, top). Both
cancer-associated mutp53 isoforms further increased vitamin
D3-induced transcription. Importantly, wtp53 failed to augment
the transcriptional activity of this promoter. Neither the
p53R175H22,23 triple mutant, possessing a defective transacti-
vation domain (TAD), nor p73DD, which has a dominant-negative
effect over both p63 and p73, had any effect on transcription
(Figure S1C; see also Figure S4E). Hence, the effects of
mutp53 in our experimental models are mostly independent of
other p53 family members, but require a functional p53 TAD.
Next, the same reporter plasmids were transfected into
SKBR3 cells together with siRNA oligonucleotides specific for
p53 (p53i) or LacZ as a control (LacZi). As expected, vitamin
D3 induced a robust increase in transcription from a promoter
containing wild-type but not mutant VDRE (Figure 1B, bottom).
Importantly, knockdown of endogenous mutp53 reduced both
basal and vitamin D3-induced transcription. Similar results
were obtained with SW480 colorectal cancer cells expressing
H273R mutp53 (Figure S1D). Hence, mutp53 can cooperate
with vitamin D3 to maximize VDRE-dependent transcription, at
least from some promoters.
Mutp53 Increases Nuclear VDR Levels
The VDR gene is a transcriptional target of wtp53 (Maruyama
et al., 2006) as well as of p63 and p73 (Kommagani et al.,
2006, 2007). p63/p73 activity can be quenched by mutp53;
indeed, p53R248W can elicit a dominant-negative effect over
transfected p73 in the regulation of VDR gene transcription
(Kommagani et al., 2006, 2007). Knockdown of mutp53 in either
SKBR3 orMDA-MB-231 cells caused a 30% to 50% reduction in
total VDR protein (Figure 2A, top panel) but had no significant
impact on VDR mRNA levels (data not shown), which suggests
that mutp53 may lead to a mild stabilization of VDR. In
H1299R175H-i cells, induction of mutp53 expression by Zn2+
led to only a slight (30%) increase in VDR mRNA (Figure 2B)
and a mild (1.4-fold) increase in total VDR protein (Figure 2C,
lanes 1 and 2).
Transcriptional activation by vitamin D3 requires translocation
of VDR into the nucleus. We therefore examined the effect of
mutp53 on VDR localization 3 hr after addition of vitamin D3.
Remarkably, mutp53 had a dramatic effect on the amount of
VDR in the nuclear fraction (Figures 2A and 2C). Immunostaining
analysis revealed that while in untreated H1299R175H-i cells
VDR is largely cytoplasmic, vitamin D3 caused a substantial
nuclear translocation of VDR in some cells (Figure 2D, top twoCancer Cell 17, 273–285, March 16, 2010 ª2010 Elsevier Inc. 275
Figure 1. Mutp53 Associates with VDREs
and Augments Transcription from Such
Elements
(A) SKBR3 cells expressing p53R175H, trans-
fected with either siRNA for p53 (sip53) or control
siRNA (sicontrol) and treated with 1a25(OH)2D3
(D3;100nM), were subjected to ChIP with anti-
bodies against p53 or VDR or with a non-specific
antibody as a negative control. The precipitated
DNAwas subjected to real-time PCR amplification
using sets of primers specific to either ChIP
control (negative control) or regions of the HIRA
and TGF-b1 gene promoters spanning putative
VDREs. Results are presented relative to the
values obtained with an aliquot of the input chro-
matin corresponding to 1% of the total material.
The results of HIRA and TGF-b1 gene promoters
are presented as enrichment fold over non-
specific antibody and are also normalized to
values obtained for the ChIP control results.
(B) Reporter plasmids were either cotransfected
together with mutp53 expression plasmids
(R175H or R273H) into p53 null H1299 cells (top)
or cotransfected with synthetic p53i or LacZi into
SKBR3 cells (bottom). Cells were either treated
with 1a25(OH)2D3 (D3; 100 nM) for the indicated
times or left untreated (nt). Values shown repre-
sent fold activation relative to the PGL3-promoter
empty vector reading. See also Figures S1C and
S1D. All scale bars represent ± SD.
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translocation of VDR inmany cells without vitamin D3 (Figure 2D,
third row). Moreover, cells expressing high amounts of mutp53
exhibited more pronounced nuclear VDR staining. Furthermore,
combining mutp53 induction with vitamin D3 rendered VDR
staining more prominent and almost exclusively nuclear (Fig-
ure 2D, bottom row). The ability of mutp53 to enhance the
nuclear translocation and accumulation of VDR probably con-
tributes to the augmented vitamin D3-induced transcription.
Mutp53 Physically Interacts with VDR
Mutp53 may be tethered to VDRE elements through a complex
with VDR/RXR. To explore the existence of such a complex,
coimmunoprecipitation analysis was performed on SKBR3
cells with or without treatment with 100 nM vitamin D3. As a
control for wtp53, a similar experiment was performed on
MCF7 cells treated with Nutlin-3A to induce p53 accumulation.
As seen in Figure 3A (top), pull-down of VDR coprecipitated276 Cancer Cell 17, 273–285, March 16, 2010 ª2010 Elsevier Inc.p53 from both SKBR3 and MCF7 cell
extracts, indicative of a complex com-
prising both proteins. This interaction
was significantly increased by treatment
with vitamin D3. Reciprocal coimmuno-
precipitation yielded a similar picture
(Figure 3A, bottom). Interestingly, the
coimmunoprecipitation of mutp53 with
VDR was further augmented when a
wild-type, but not mutant, VDRE con-
sensus oligonucleotide was added to
the cell extract during incubation (Fig-ure S2A), indicating that the VDRE sequence can recruit both
proteins simultaneously.
The p53 protein is composed of three major domains: an
N-terminal TAD, a central DBD, and a C-terminal regulatory
domain. VDR was overexpressed in H1299 cells together with
either full-length H175Rp53, DN-H175Rp53 (aa 97–393), or
DC-H175Rp53 (aa 1–292) or the DBD of H175Rp53 (aa 97–
292). Pull-down of VDR followed by western blot analysis for
p53 revealed that full-length H175Rp53 and DN-H175Rp53
bound VDR, whereas DC-H175Rp53 and DBD-H175Rp53 did
not (Figure 3B); hence, the interaction between p53 and VDR is
mediated through the p53 C-terminal regulatory domain.
Knockdown of Mutp53 Attenuates the Transcriptional
Response to Vitamin D3
Next, we knocked down mutp53 expression in SKBR3 cells, in
SW480 colorectal cancer cells that harbor a combination of the
p53R273H and p53P309S mutations, and in MCF7 cells that
Figure 2. Mutp53 Increases Nuclear VDR
Levels
(A) SKBR3 and MDA-MB-231 cells were trans-
fected with p53i or control siRNA (ConSi; Dharma-
con) as negative control. Forty eight hours after
transfection, cells were treated with 100 nM
1a25(OH)2D3 for 3 hr. Nuclear extracts were then
prepared, subjected to SDS-PAGE, and followed
by western blot analysis with antibodies directed
against p53 or VDR.
(B) H1299R175H-i cells were either left untreated
(nt) or maintained for 12 hr either with or without
100 mM Zn2+, and then 100 nM 1,25(OH)2D3 (D3)
was added for an additional 24 hr where indicated.
Cells were harvested, RNA was extracted, and
qRT-PCR was performed with primers specific
for VDR or GAPDH. Relative levels of VDR mRNA
were normalized to GAPDH.
(C) H1299R175H-i cells were either induced with
100 mM Zn2+ (+) or not induced (). Eight hours
later, 100 nM 1a25(OH)2D3 was added for 3 hr to
all cultures. Part of each sample was extracted
directly (whole cell extract; WCE). Nuclei were
prepared from the rest of the sample and extracted
(nuclear extract; NE). Extracts were subjected to
SDS-PAGE, followed by western blot analysis
with antibodies directed against p53 or VDR. Rela-
tive intensities of the VDR bands are indicated
below each band. The bottom panel shows Pon-
ceau staining of the corresponding region of the
membrane. All error bars represent ± SD.
(D) H1299R175H-i cells were seeded on cover-
slips. One day later, 100 nM Zn2+ was added for
12 hr where indicated to induce mutp53 expres-
sion, and then 1a25(OH)2D3 (D3) was added for
an additional 5 hr where indicated. Cells were fixed
with 4% paraformaldehyde, incubated with poly-
clonal anti-VDR antibody and monoclonal anti-
p53 antibody, and followed by suitable secondary
antibodies conjugated to Cy5 or Cy3, respectively.
Nuclei were visualized by DAPI staining. Nuclear
VDR intensity was quantified using the Volosity
software (PerkinElmer, Inc.), and is presented as
percentage of total VDR staining. All pictures
were taken with the same exposure time. All scale
bars represent a size of 27 mm.
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genes revealed that vitamin D3 caused a dramatic increase in
CYP24A1 mRNA and a 3-fold induction of IGFBP3 mRNA in
both SW480 and SKBR3 cells (Figure 3C), which was attenuated
by knockdown of endogenous mutp53. Hence, mutp53 is
required for an optimal transcriptional response of at least
some genes to vitamin D3. In contrast, knockdown of wtp53 in
MCF7 cells had no significant effect on either endogenous or
vitamin D3-induced mRNA levels of CYP24A1 and IGFBP3.
Mutp53 Enhances Transcription by Recruiting VDR
and p300 to VDRE of Target Genes
p53 can transactivate its target genes by recruiting transcrip-
tional coactivators such as CBP/p300. Furthermore, both
wtp53 and mutp53 interact with CBP/p300 through their TADs
(Avantaggiati et al., 1997; Gu et al., 1997).We therefore assessed
the binding of mutp53, VDR, and p300 to VDRE in the CYP24Apromoter. As seen in Figure 3D, mutp53, VDR, and p300 showed
comparable binding (4- to 8-fold enrichment over control) under
basal conditions. As expected, vitamin D3 strongly increased the
binding of VDR and p300. Binding of p53R175H to the CYP24A
promoter also increased significantly, to 20-fold over back-
ground. Importantly, mutp53 knockdown significantly reduced
both basal and vitamin D3-induced binding of all three proteins.
Hence, mutp53 augments the recruitment of both VDR and p300
to VDRE-containing chromatin. To confirm the interaction of
VDR, mutp53, and p300 with the same DNA segment, we per-
formed a re-ChIP experiment. As seen in Figure 3E, ChIP for
p53 followed by re-ChIP for VDR or p300 enriched for the pres-
ence of the CYP24A VDRE when treated with vitamin D3.
Mutp53 Compromises Vitamin D3-Mediated Repression
Vitamin D can also repress many genes, including CYP27B (Kim
et al., 2007; Murayama et al., 2004), by a mechanism involvingCancer Cell 17, 273–285, March 16, 2010 ª2010 Elsevier Inc. 277
Figure 3. Mutp53 Binds VDR and Augments the Transcriptional Response of Classical VDR Target Genes to Vitamin D3
(A) SKBR3 andMCF7 cells were either grown in charcoal-stripped serum-supplementedmedium (D3) or treatedwith 1a25(OH)2D3 (+D3) for 3 hr; theMCF7 cells
were pretreated with Nutlin (40 mM, 24 hr) to induce wtp53 levels. Cell extracts were subjected to immunoprecipitation with either mutp53-specific antibody
PAb240, anti-VDR antibody C-20 (Santa Cruz Biotechnology), or control antibody (PAb419, directed against SV40 large T-antigen; ns). Immunoprecipitated
proteins were subjected to SDS-PAGE, followed by western blot analysis with antibodies against p53 (p53-HRP; R&D Systems; bottom panels) or VDR
(top panels). See also Figures S1B and S2A.
(B) H1299 cells were transfected with a VDR expression plasmid together with plasmids expressing either full-length H175Rp53, DN-H175Rp53 (aa 97–393), or
DC-H175Rp53 (aa 1–292) or the DBD of H175Rp53 (DBD; aa 97–292). Total protein input levels are shown in the left panel. Cells were treated with 1a25(OH)2D3
for 3 hr and cell extracts were subjected to immunoprecipitation with either anti-VDR C-20 (Santa Cruz Biotechnology) or PAb419 as a non-specific control
(ns Ab). Immunoprecipitated proteins were analyzed as in (A).
(C) SKBR3 and SW480 cells were transfected with p53i or LacZi as negative control. After 24 hr, 1a25(OH)2D3 (D3; 100 nM) was added for 24 hr where indicated.
Cells were harvested, RNA was extracted, and qRT-PCR was performed with primers specific for IGFBP3, CYP24A1, or GAPDH. Relative levels of IGFBP3 and
CYP24A1 mRNA were normalized to GAPDH expression. See also Figures S2B and S2C.
(D) SKBR3 cells were transfected with either p53 siRNA (sip53) or control siRNA (si control) and treated with 1a25(OH)2D3 (D3;100 nM, 2 hr) or left untreated. Cells
were subjected to ChIPwith antibodies directed against either p53, VDR, p300, or non-specific antibody (ns Ab). The precipitated DNAwas subjected to real-time
qPCR amplification using sets of primers specific to a region of the CYP24A promoter spanning the VDRE. Results are presented as fold over non-specific
antibody.
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Figure 4. Mutp53 Converts Vitamin D3
from a Proapoptotic into an Antiapoptotic
Effector
(A) MCF7 cells stably transfected with empty
vector (Cont) or with p53 shRNA expression
plasmid to knockdown endogenous wtp53 (p53i)
were seeded in a 96 well plate at 5000 cells/well.
After 24 hr, 1a25(OH)2D3 (D3; 100 nM) was added
for 48 hr where indicated. Cisplatin (Cis-DDP;
5 mg/ml) was then added for 24 hr, and cells
were harvested and monitored under the micro-
scope for trypan blue dye exclusion. At least
150 cells/assay were counted; the percentage of
dead (trypan blue-positive) cells is shown. NT,
not treated.
(B) SKBR3 cells were seeded in a 96 well plate at
8000 cells/well. Cells were transfected with p53i
or LacZi as control. Twenty-four hours later,
100 nM 1a25(OH)2D3 (D3) was added for 48 hr
every 24 hr, followed by treatment with cisplatin
(Cis-DDP; 2 mg/ml) or etoposide (Eto; 5 mM) for
24 hr. Caspase activity was measured using the
caspase 3/7 activity assay (Promega). Caspase
activity readings were normalized for the corre-
sponding WST-1 cell proliferation assay (Roche)
readings of the same samples. NT, not treated.
See also Figures S3C, S4D, and S3G for Annexin
V and PI assays.
(C) MDA-MB231 cells were seeded and treated
and the results were analyzed as in (B). See also
Figures S3D–S3H for Annexin V and PI assays.
(D) EP-156-neo cells were seeded as in (A).
Twenty-four hours later 100 nM 1,25(OH)2D3
(D3) was added for 72 hr, followed by treatment
with doxorubicin (Dox; 1.5 mg/ml) or etoposide
(Eto; 9 mM). Caspase activity was quantified as in
(B) and normalized to cell number.
(E) EP-156-p53R175H cells were analyzed as in
(D). All scale bars represent ± SD.
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Figure 3F, vitamin D3 caused a significant repression of
CYP27B only in mutp53-depleted (p53i+D3) but not mutp53-
proficient (LacZi+D3) SKBR3 cells, arguing thatmutp53 prevents
VDR-mediated transrepression. Mutp53 was not associated
with the region of the CYP27B gene harboring the nVDRE
(Figure 3G). Remarkably, while in cells depleted of mutp53
vitamin D3 strongly stimulated the binding of VDR, presumably
to the nVDRE, this was attenuated by mutp53. Furthermore,
while vitamin D3 caused a dissociation of p300 from this region
in the absence of mutp53, p300 remained associated when
mutp53 was present. These results imply that mutp53 interferes(E) MDA-MB-231 cells grown in medium containing charcoal-stripped serum,
(white bars), and then subjected to ChIP with antibodies directed against p53. T
cipitation was performed with antibodies against VDR, p300, or non-specific ant
(F) RNA was prepared from the experiment shown in (C) and subjected to qRT-P
(G) Immunoprecipitated DNA from experiment shown in (D) was subjected to r
promoter spanning the nVDRE. Results are presented as fold over non-specificwith the binding of VDR to nVDRE, enabling the relevant target
genes to remain transcriptionally active.
Vitamin D3 Exerts Mutp53-Dependent Antiapoptotic
Effects
Vitamin D has been reported to promote tumor cell death (Deeb
et al., 2007; Duque et al., 2004). Indeed, vitamin D3 slightly
augmented the death of wtp53-positive MCF7 breast cancer
cells (Figure 4A). This effect increased modestly when vitamin
D3 was combined with cisplatin treatment (Figure 4A, Cis-DDP)
and was somewhat attenuated by endogenous wtp53 knock-
down (p53i).or treated with 1a25(OH)2D3 (gray bars; D3; 100 nM, 2 hr) or left untreated
he immunoprecipitated chromatin was eluted and then a second immunopre-
ibody (ns Ab) as a negative control. Real-time qPCR was performed as in (D).
CR analysis with primers specific for CYP27B.
eal-time PCR amplification with primers specific to a region of the CYP27B
antibody. All scale bars represent ± SD.
Cancer Cell 17, 273–285, March 16, 2010 ª2010 Elsevier Inc. 279
Cancer Cell
Mutp53 GOF Mechanism through Interaction with VDRSurprisingly, vitamin D3 significantly reduced cisplatin- and
etoposide-induced apoptosis of SKBR3 cells, as measured by
caspase activity (Figure 4B and Figure S3B) or Annexin V or PI
assays (Figures S3C and S3F). This protective effect was strictly
mutp53 dependent, since it was abolished upon knockdown of
endogenous p53R175H. Thus, while vitamin D often promotes
apoptosis in cells lacking mutp53, mutp53 can convert vitamin
D3 into a cytoprotective agent. A similar pattern was seen in
an SKBR3-derived cell line expressing inducible p53 shRNA
(Figure S3B).
Mutp53-dependent antiapoptotic activity of vitaminD3was also
observed in two other breast cancer cell lines, MDA-MB-231 that
harbors endogenous p53R280K (Figure 4D and Figure S3D) and
MDA-MB-468thatexpressesendogenousp53R273H(FigureS3E),
and a colorectal cancer cell line, SW480 that expresses p53R273H
and p53P309S (Figure S3F). Furthermore, vitamin D3 led to a mild
but consistent increase in colony formation of H1299 cells trans-
fected with various mutp53 isoforms but not with GFP control
plasmid (Figure S3I). However, in the breast cancer cell line
BT474, which expresses p53E285K, vitamin D3 protection was
not significant (data not shown). Hence, even though the observed
effects are common to many mutp53-expressing tumor cells, the
scope of the effect is cell context dependent.
To compare the impact of wtp53 and mutp53 on the biological
response to vitamin D in a genetically defined experimental
model, we used primary prostate epithelial cells immortalized
by the introduction of hTERT and then transfected with either an
empty vector (EP-156-neo cells) or amutp53 expression plasmid
(EP-156-p53R175H cells) (Kogan et al., 2006). EP-156-neo cells
express endogenous wtp53 whereas EP-156-p53R175H cells
overexpress p53R175H on the background of wtp53. As seen
in Figure 4E, treatment of EP-156-neo cellswith vitaminD3, either
alone or in combination with genotoxic agents, had a mild proa-
poptotic effect. However, mutp53 altered the response dramati-
cally: instead of enhancing apoptosis, vitamin D3 now conferred
strong protection (Figures 4D and 4E). Hence, p53 mutations
convert vitamin D3 from death promoting into protective.
Mutp53 Modifies the Vitamin D Transcriptional Program
Althoughmutp53 exerts a general stimulatory effect onVDR tran-
scriptional activity, this by itself cannot explain how mutp53
reverses the impact of vitamin D on apoptosis. Rather, the
answer might lie in differential effects on the expression of spe-
cific genes. Therefore, expression microarray analysis was per-
formed on SKBR3 cells without or with endogenous mutp53
knockdown, with or without vitamin D3 treatment. The expres-
sion level of each individual gene in cells transfected with p53
siRNA but not treated with 1a25(OH)2D3 (equals no mutp53, no
vitamin D), averaged from two biological repeats, was taken as
baseline. Relative expression levels of each gene in the other bio-
logical samples were calculated as fold change over baseline.
Genes were then sorted according to their fold induction by
vitamin D3, mutp53, or the combination of both. When we
analyzed the genes most highly induced by mutp53 (Table S2),
vitamin D3 association was strongly significant (31 out of
38 genes, excluding the twop53probes; p= 43 1018, Student’s
t test). Hence, in SKBR3 cells, most mutp53-upregulated genes
are also VDR targets, implicating the interaction with VDR as
a major regulatory mechanism by mutp53 in these cells.280 Cancer Cell 17, 273–285, March 16, 2010 ª2010 Elsevier Inc.Figure 5A illustrates the effects of mutp53 and vitamin D on
gene expression. The x axis shows the effect of vitamin D3 alone
on each gene, calculated from the ratio between expression
levels with and without vitamin D3 (50 hr) in mutp53 knocked
down cells. The y axis shows the combined effect of vitamin
D3 and mutp53, calculated from the ratio between expression
levels with vitamin D3 in control cells and without vitamin D3 in
mutp53 knocked down cells. Most genes are along the diagonal,
near the center of the plot, indicating lack of regulation by either
vitamin D3 or mutp53. A few genes lie further up or down on the
diagonal: these are regulated by vitamin D3, but the extent of
regulation is not affected by mutp53. On that background,
several gene clusters exhibit distinct response patterns that
diverge from the behavior of the bulk transcriptome.
Cluster 1 (blue) contains genes that are highly induced by the
combination of mutp53 and vitamin D3, a behavior consistent
with the luciferase experiments. Many classical VDR target
genes populate this cluster. Of note, the majority of those genes
are also dependent on mutp53 for optimal basal level expres-
sion, as revealed by comparison of non-treated samples without
(Figure 5B, lanes 1 and 2) and with (lanes 6 and 7) p53 siRNA.
This suggests that a functional interaction between VDR and
mutp53 may exist even without vitamin D3 or at low residual
levels of vitamin D3 produced by SKBR3 cells.
Cluster 2 (red) comprises genes repressed 3-fold or more by
long (50 hr) treatment with vitamin D3 when mutp53 was absent,
but this effect was strongly attenuated in the presence of mutp53
(Figure 5C, compare lanes 5 and 10). These results are consistent
with the data obtained for theCYP27B gene (Figures 3F and 3G).
Hence, in addition to augmenting the transactivation of many
vitamin D3-inducible genes, mutp53 also relieves vitamin
D3-mediated repression of a relatively large subset of genes.
Cluster 3 (green) contains geneswhose expression was down-
regulated more than 4-fold by the combination of mutp53 and
vitamin D3. The basal expression level of most genes in the
cluster was repressed by mutp53 even without vitamin D.
Vitamin D3, however, caused a further repression in cells ex-
pressing mutp53 but not in mutp53 knocked down cells. Hence,
these genes are repressed by vitamin D3 in amutp53-dependent
manner.
Apoptosis-Regulating Genes Are Differentially Affected
by Vitamin D and Mutp53
The microarray analysis in Figure 5 demonstrated that mutp53
can modulate the activity of VDR in a gene-specific manner.
The impact of mutp53 on the biological response to vitamin D
suggested that mutp53mightmodify the transcriptional program
of VDR in a manner conducive to increased resistance to
apoptosis. qRT-PCR analysis of individual transcripts further
supports this conjecture (Figure S4A). Thus, mutp53 augmented
the ability of vitamin D to upregulate genes reported to promote
survival and neoplastic transformation [e.g., SEMA3C (Moreno-
Flores et al., 2003), Wnt5A (Ripka et al., 2007), and CSF3R] or
to be overexpressed in cancer [e.g., Klk6 (Klucky et al., 2007)].
Remarkably, mutp53 prevented the vitamin D-dependent
repression of MAP2K5 and FGFR2, survival-promoting genes
overexpressed in some cancers (Acevedo et al., 2007). Con-
versely, the combination of mutp53 and vitamin D repressed
the proapoptotic XAF1 (Lee et al., 2006), CYFIP2 (Jackson
Figure 5. Expression Array Analysis of the
Effects of Vitamin D3 and Mutp53
(A) Graphic representation of the relative effects of
1a25(OH)2D3 (vitamin D) and mutp53 on gene
expression. The x axis shows a log2 scale of
1a25(OH)2D3 fold activation/repression, calcu-
lated by dividing the expression level reading of
each individual gene in the p53i-D3 50 hr sample
by the average of the two corresponding p53i
basal level (no vitamin D) samples; this represents
the effect of 1a25(OH)2D3 in the absence of
mutp53. The y axis shows a log2 scale of the
combined effect of 1a25(OH)2D3 and mutp53,
calculated by dividing the expression level reading
of each gene in the LacZi-D3 48 hr sample by the
average of the two corresponding p53i basal level
(no vitamin D) samples. Different colors identify
genes belonging to the three different clusters
denoted by the same colors in (B)–(D).
(B) Cluster 1 (blue), obtained by imposing a 4-fold
upregulation cutoff threshold on the y axis, con-
tains genes highly induced by the combination of
mutp53 and 1a25(OH)2D3 (50 hr). Values of gene
expression range from 0.7 (blue) to +0.6 (red).
(C) Cluster 2 (red) contains genes that were
repressed more than 3-fold by 1a25(OH)2D3 in
the absence of mutp53; most of those genes
were repressed less well by 1a25(OH)2D3 when
mutp53 was present.
(D) Cluster 3 (green) includes genes whose ex-
pression was significantly repressed by the com-
bination of mutp53 and 1,25(OH)2D3. See also
Figures S4A–S4F.
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Mutp53 GOF Mechanism through Interaction with VDRet al., 2007), DAPK1 (Raval et al., 2007), and TXNIP (Billiet et al.,
2008) genes. Interestingly, the first three are transcriptional
targets of wtp53 (Jackson et al., 2007; Lee et al., 2006; Martoriati
et al., 2005). The strong repression of those genes may underpin
in part the cytoprotective program installed by vitamin D in
mutp53-harboring cells.
To demonstrate that the transcriptional effects of mutp53
siRNA were not due to off-target effects, we performed a rescue
experiment using an siRNA-resistant p53R175H expression
plasmid. As shown in Figures S2B and S2C, restoration of
mutp53 expression reversed the effect of mutp53 knockdown
on specific gene expression. Furthermore, it also reversed the
proapoptotic effects of the knockdown (Figure S2D). The
expression pattern of these genes in additional experimental
systems showed a similar trend to that of SKBR3 (Figures
S4B–S4D), attesting to the generality of the transcriptional cross-
talk between mutp53 and VDR.
The differential behaviors of the different clusters and the
identities of some of the genes offer an attractive explanation
for the mutp53-dependent antiapoptotic effects of vitamin D3.Cancer Cell 17, 273–28DISCUSSION
The present study reveals a functional
and physical interaction between
mutp53 and the vitamin D transcriptional
regulatory pathway. Specifically, mutp53
is tethered to chromosomal regions con-taining VDRE elements, presumably through association with
VDR and to augment transcription from promoters containing
such elements. Moreover, in cells harboring p53 mutations,
mutp53 cooperates with vitamin D3 to elicit an antiapoptotic
state. This surprising effect of mutp53 is likely due to its ability
to modulate, qualitatively and quantitatively, the transcriptional
program orchestrated by VDR and appears to involve
augmented expression of survival genes along with reduced
expression of proapoptotic genes.
Vitamin D participates in diverse biological processes such as
calcium homeostasis, cell proliferation, and cell differentiation
(for review see Deeb et al., 2007). VDR is believed to be
constantly transported into the nucleus; however, after activa-
tion by vitamin D3, this transport is greatly enhanced (Yasmin
et al., 2005). Ligand binding induces conformational changes
in VDR, exposing surfaces for transcriptional coactivator binding
and dimerization. The dimerization partner is usually RXR, which
is required for full transactivation by VDR. Dimerization enables
high affinity interaction with the VDRE. Transcriptional coactiva-
tors, physically recruited by VDR, then initiate transcription.5, March 16, 2010 ª2010 Elsevier Inc. 281
Figure 6. Cartoon of the Proposed Model
for the Crosstalk between Mutp53 and the
VDR Pathway
The model displays the impact of mutp53 on
VDR-mediated transactivation (top) and transre-
pression (bottom). TSS, transcription start site;
TF-X, positive transcription site (e.g., VDIR) that
is displaced/inactivated by VDR. See Discussion
for further details.
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Mutp53 GOF Mechanism through Interaction with VDRWe show that VDR and mutp53 (and also wtp53) engage in
a physical interaction, which is significantly enhanced by vitamin
D3 treatment. The high endogenous levels of mutp53 in tumor
cells probably enable this interaction to exert significant biolog-
ical effects. Moreover, mutp53 increases the nuclear accumula-
tion of VDR. Notably, in lung tumors, increased nuclear localiza-
tion of VDR correlates with higher histological grade (Menezes
et al., 2008). Remarkably, some enhancement of VDR nuclear
accumulation by mutp53 can be seen even in the absence of
added vitamin D. Thus, the binding of mutp53 to VDRmight alter
the latter’s conformation in a way that mimics the effect of
vitamin D3.
Increased nuclear localization of VDR is probably not the sole
explanation for the effect of mutp53. Based on our findings, we
propose the following additional mechanisms (Figure 6). In the
case of transactivation, VDR recruits mutp53 to VDREs in target
genes, and mutp53 increases VDR-dependent transcription by
augmenting the recruitment of additional transcriptional coacti-
vators, such as p300 (Figure 6, top). Indeed, p300 binds to the
p53 TAD, which is intact in all cancer-associated hotspot p53
mutants.
The mechanism behind vitamin D3-mediated transrepression
is less well characterized. A distinct nVDRE was identified in the
promoters of several vitamin D3-repressed genes. nVDRE binds
the transcriptional activator VDIR, which in turn recruits p300 and
activates transcription. VDR, activated by vitamin D3, does not
directly bind the nVDRE, but instead associates with VDIR.
This leads to dissociation of p300 and recruitment of HDACs
to repress transcription of the target gene. In contrast to the posi-
tive effect of mutp53 on VDR-mediated transactivation, mutp53
actually reverses VDR-mediated transrepression. In fact, the
majority of genes repressed by vitamin D3 in SKBR3-p53i cells
were derepressed in cells expressing endogenous p53R175H282 Cancer Cell 17, 273–285, March 16, 2010 ª2010 Elsevier Inc.(Figure 5, red cluster). As an example,
VDR binds the nVDRE-containing region
of the CYP27B promoter only in the
absence of mutp53 and presence of
vitamin D3, and this leads to dissociation
of p300 (Figure 3G) and transcriptional
repression (Figure 3F). We therefore
propose that while VDR can repress tran-
scription by interfering with the binding
and activity of positive transcription
factors (Figure 6, bottom, TF-X), such as
VDIR, engagement of VDR by mutp53
relieves this interference, allows recruit-
ment of transcriptional coactivators, and
restores transcription.Vitamin D3 can induce apoptosis either alone or in conjunction
with other drugs (Colston et al., 1992; Nakagawa et al., 2005).
Moreover, vitamin D3 has been reported to possess anti-tumor
activities (Kerner et al., 1989). VDR knockout mice exposed to
the chemical carcinogen DMBA develop more skin tumors and
lymphomas than wild-type mice, and nearly all VDR knockout
mice display in situ hyperplasia of the mammary gland (Zinser
et al., 2002a, 2002b). The notion that vitamin D3 is capable of
exerting anti-cancer effects has spurred attempts to develop
vitamin D3 analogs as cancer chemotherapy agents.
However, in addition to the well documented proapoptotic
effects, there are circumstances where vitamin D3 exerts antia-
poptotic effects, including increased cell survival following UV
trauma and protection of some cancer cell lines from killing by
cytotoxic drugs. An inhibitory effect of vitamin D3 on TNF-a-
induced apoptosis and on TRAIL and Fas ligand-induced
apoptosis, accompanied by a decrease in Bax and upregulation
of Bcl2 and p21, has also been described (Wang et al., 1999;
Duque et al., 2004). However, in SKBR3 andMDA-MB-231 cells,
p21 and Bcl2 protein levels did not change significantly following
either mutp53 knockdown or vitamin D3 treatment (Figure S3J).
Interestingly, VDR is upregulated in several types of cancer,
including breast and ovarian carcinomas (Friedrich et al., 1998,
2002). Moreover, elevated VDR was reported to correlate with
tumor stage (Menezes et al., 2008; Sahin et al., 2005). Thus,
the VDR pathway can lead to either death or survival, depending
on the cellular context.
To date, no satisfactory mechanism was proposed to account
for the seemingly conflicting effects of VDR/vitamin D3. Our find-
ings now provide a possible explanation. Perhaps the most
significant finding is that mutp53 can convert vitamin D3 from
a proapoptotic agent into an antiapoptotic one. In support of
this notion, vitamin D3 suppresses death receptor-mediated
Cancer Cell
Mutp53 GOF Mechanism through Interaction with VDRapoptosis in OVCAR3 ovarian carcinoma cells (Zhang et al.,
2005b), which harbor endogenous mutp53. Conceivably, some
cancers might have evolved a mechanism that allows them to
capitalize more efficiently on the survival route of VDR while
evading its proapoptotic effects. Our data suggests that acquisi-
tion of GOF p53mutations may constitute one such mechanism.
Obviously, p53 mutations alone are not sufficient to drive the
conversion of the VDR pathway into an antiapoptotic one, as
not all mutp53-expressing tumor-derived cell lines are equally
protected by vitamin D3. Thus, additional alterations most likely
cooperate with mutp53 to orchestrate the antiapoptotic
response to vitamin D3. Identification of such cooperating
factors remains an important challenge.
Vitamin D and its derivatives are being extensively explored as
cancer-preventive and even cancer-therapeutic agents. Our
findings call for extra caution in exploring this approach. Con-
versely, individualized cancer therapy might be implemented
also in the context of vitamin D3 treatment, where the p53 muta-
tion status of the tumor may serve as an important aid for
outcome prediction.EXPERIMENTAL PROCEDURES
Cell Lines
H1299 human non-small cell lung cancer cells and SKBR3 breast cancer cells
were maintained in RPMI-1640 medium supplemented with 10% fetal calf
serum (FCS) and antibiotics. Where indicated, charcoal-stripped serum was
included instead of regular serum. MCF7 human breast cancer cells stably
expressing shRNA targeting p53, as well as vector control cells (gift of
R. Agami, Netherlands Cancer Institute) were grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% FCS, 2 mM L-glutamine,
and antibiotics. The MDA-MB-231 breast cancer cell line and the SW480 colo-
rectal cancer cell line were maintained in DMEM supplemented with 10% FCS
and antibiotics. EP156 epithelial cells were grown as described previously
(Kogan et al., 2006). SKBR3-D8 cells were grown under the same conditions
as parental SKBR3, plus puromycin (1 mg/ml) and blasticidin (10 mg/ml). All
cell lines were grown at 37C in a humidified atmosphere of 5% CO2 in air.
Plasmids
Expression plasmids for wild-type human p53 and mutant p53R175H were
gifts from C.C. Harris (National Cancer Institute, Bethesda, MD). Reporter
plasmids were constructed by inserting a 64 bp DNA fragment containing
either three tandem VDRE sequences (AGGTCAnnnAGGTCA) separated by
5 bp spacers or a derivative that contained two point mutations in each half
VDRE site (mVDRE: ATATCAnnnATATCA) upstream of the luciferase reporter
gene within the PGL3-promoter plasmid (Promega).
Luciferase Assays
Cells were seeded in 24 well culture dishes. Each well was transfected with
VDRE-luciferase or mVDRE-luciferase, together with increasing amounts of
various p53 expression plasmids and b-galactosidase plasmid. Luciferase
activity was assayed 48 hr after transfection. Each plasmid combination was
transfected into three identical wells. Luciferase assays were performed using
(D)-luciferin (Roche). Luminescence was determined with the aid of a Rosys-
Anthos Lucy 3 luminometer. Luciferase values were normalized to b-galacto-
sidase activity.
Immunofluorescence Microscopy
Immunofluorescence microscopy was performed as described previously
(Kalo et al., 2007). Incubations with antibodies for VDR and/or p53were carried
out for 45 min at 22C, with three extensive washes after each step. Cells were
mounted with Prolong Antifade (Invitrogen). Fluorescence digital images were
recorded on a Zeiss Axio Imager microscope (Carl Zeiss).Coimmunoprecipitation
Coimmunoprecipitation was performed as described previously (Kalo et al.,
2007). Cells were treated with 100 nM 1a25(OH)2D3 for 3 hr. Cells were then
scraped into ice-cold PBS and lysed with lysis buffer. Monoclonal anti-p53
antibody PAb240 or control anti-SV40 Large T antigen Pab419 antibody
were incubated with 30 ml protein A for 1 hr at room temperature and added
to the lysate. Immune complexes were precipitated overnight at 4C. The
immunoprecipitated material was washed and pellets were resuspended in
SDS sample buffer and subjected to western blot analysis.
Chromatin Immunoprecipitation
ChIP was performed as described previously (Stambolsky et al., 2006) using
protein A beads crosslinked by DMP to anti-p53 polyclonal antibodies,
anti-HA antibodies, or anti-VDR antibodies (C20; Santa Cruz Biotechnology).
DNA samples were extracted using PCR clean-up mini-columns (Promega).
Real-time PCR was performed using Sybr Green as described above.
Promoter Array Analysis
Samples of immunoprecipitated DNA and 0.02% of the input DNA (calibrated
to be the equivalent of background binding) were amplified by linker-mediated
PCR and subjected to ChIP-on-chip analysis as described (Odom et al., 2004),
using 1 mg of polyclonal anti-p53 antibody (H47; homemade) and the Hu13K
human promoter array. A whole-chip error model (Simon et al., 2001) was
used to calculate confidence values for each spot.
Analysis of Transcription Factor Motifs
Search for enriched transcription factor binding motifs in microarray data used
the MathInspector library of 414 PSSMs maintained by Genomatix (Release
4.1) (Quandt et al., 1995) and a customary promoter to PSSM assignment
score (Elkon et al., 2003). A threshold on this score was defined, above which
a PSSM was considered assigned to a promoter. For this purpose, the
promoters of coregulated genes were used for a range of potential values of
the calculated threshold score, using the hypergeometric statistics, and the
group’s specificity score (Hughes et al., 2000) of the motif relative to the genes
in the cluster. A threshold score that minimizes the hypergeometric probability
function was then identified and adopted.
Cell Death Assays
To monitor apoptosis, cultures were subjected to a caspase activity assay
(Promega). To that end, cells were seeded in 96 well plates. The next day,
either 1a25(OH)2D3 or DMSO was added. After an additional 24 hr cells
were subjected to different treatments (e.g., anti-cancer drugs) for various
times and harvested by adding lysis buffer to the cells, and fluorescence
was monitored several hours later. Values were normalized either for cell
number or for readings of a WST1 kit assay (Roche), as indicated in the corre-
sponding figure legends. For cell viability assessments, the trypan blue dye
exclusion method was used, counting a minimum of 150 cells/assay and
expressing data as a percentage of dead (dye including) cells.
ACCESSION NUMBERS
The accession numbers assigned in the ArrayExpress public database to the
SKBR3 ChIP-on- chip experiment is E-MEXP-2538 and to the U2OS ChIP-on-
chip experiment is E-MEXP-2537. The accession number in the GEO public
database for the SKBR3 expression array experiment is GSE19670.
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